Is ELTX or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Whitehawk Therapeutics N/A -53.89% -49.97%

Which has higher earnings and valuation, ELTX or ADAG?

Adagene has higher revenue and earnings than Elicio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A Adagene $7.67M 21.18 -$17.61M N/A N/A

Is ELTX or ADAG more profitable?

Adagene's return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Adagene N/A N/A N/A

Is CMPX or ELTX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Elicio Therapeutics N/A -1,266.43% -139.94%

Do analysts prefer ORMP or ELTX?

Elicio Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 747.46%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ORMP or ELTX more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Elicio Therapeutics N/A -1,266.43% -139.94%

Elicio Therapeutics (ELTX) Competitors

$1.77 -0.11 (-5.85%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$1.81 +0.04 (+2.37%)

As of 08:42 AM Eastern

Compare

ELTX vs. WHWK, ADAG, CMPX, ORMP, and DTIL

Should you buy Elicio Therapeutics stock or one of its competitors? Elicio Therapeutics's main competitors and comparable companies include Whitehawk Therapeutics (WHWK), Adagene (ADAG), Compass Therapeutics (CMPX), Oramed Pharmaceuticals (ORMP), and Precision BioSciences (DTIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Elicio Therapeutics compare to Whitehawk Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Elicio Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 747.46%. Whitehawk Therapeutics has a consensus target price of $8.33, indicating a potential upside of 175.94%. Given Elicio Therapeutics' higher probable upside, equities analysts plainly believe Elicio Therapeutics is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Whitehawk Therapeutics' return on equity of -53.89% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 28.7% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat Whitehawk Therapeutics' score of 1.42 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Very Positive
Whitehawk Therapeutics	Positive

Elicio Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Elicio Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Whitehawk Therapeutics	$7.14M	24.11	-$20.60M	-$1.12	N/A

Summary

Whitehawk Therapeutics beats Elicio Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Adagene?

Elicio Therapeutics (NASDAQ:ELTX) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Adagene has higher revenue and earnings than Elicio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Adagene	$7.67M	21.18	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Adagene	N/A	N/A	N/A

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 28.7% of Elicio Therapeutics shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Adagene had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 4 mentions for Adagene and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat Adagene's score of 1.05 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Very Positive
Adagene	Positive

Elicio Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Adagene has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Elicio Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 747.46%. Adagene has a consensus price target of $8.67, indicating a potential upside of 252.30%. Given Elicio Therapeutics' higher probable upside, equities research analysts plainly believe Elicio Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Adagene beats Elicio Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Compass Therapeutics' return on equity of -38.71% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Compass Therapeutics presently has a consensus target price of $10.25, suggesting a potential upside of 1,096.03%. Elicio Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 747.46%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Compass Therapeutics is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Compass Therapeutics had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Compass Therapeutics and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat Compass Therapeutics' score of 0.89 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Compass Therapeutics	Positive
Elicio Therapeutics	Very Positive

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Compass Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

Elicio Therapeutics has lower revenue, but higher earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	181.57	-$66.49M	-$0.40	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Summary

Compass Therapeutics beats Elicio Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat Oramed Pharmaceuticals' score of 0.89 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Positive
Elicio Therapeutics	Very Positive

Oramed Pharmaceuticals has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	86.74	$64.05M	$4.12	1.01
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Elicio Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 747.46%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Oramed Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oramed Pharmaceuticals' return on equity of -5.17% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Summary

Elicio Therapeutics beats Oramed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Elicio Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 428.69%. Elicio Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 747.46%. Given Elicio Therapeutics' higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Precision BioSciences had 4 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Precision BioSciences and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.79 beat Precision BioSciences' score of 0.47 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Neutral
Elicio Therapeutics	Very Positive

Elicio Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Precision BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Summary

Elicio Therapeutics beats Precision BioSciences on 7 of the 13 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.93M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-0.82	11.07	204.95	19.81
Price / Sales	N/A	1,148.53	562.00	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	19.67	17.07	10.75	6.03
Net Income	-$39.57M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-4.32%	-4.42%	-2.90%	-2.34%
1 Month Performance	-11.50%	-12.47%	-7.37%	-5.31%
1 Year Performance	-83.38%	7.61%	2.97%	-2.94%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	3.2642 of 5 stars	$1.77 -5.9%	$15.00 +747.5%	-83.3%	$50.93M	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	2.8622 of 5 stars	$3.47 +1.8%	$8.33 +140.2%	+48.0%	$194.40M	$7.14M	N/A	23	Positive News
ADAG Adagene	3.8859 of 5 stars	$2.78 -1.1%	$8.67 +211.8%	+28.8%	$185.60M	$7.67M	N/A	128	Positive News
CMPX Compass Therapeutics	4.2295 of 5 stars	$0.98 -3.6%	$10.25 +942.3%	-80.0%	$183.69M	$850K	N/A	39
ORMP Oramed Pharmaceuticals	2.0402 of 5 stars	$4.20 -3.9%	N/A	+73.0%	$181.78M	N/A	1.02	13

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. WHWK, ADAG, CMPX, ORMP, and DTIL

How does Elicio Therapeutics compare to Whitehawk Therapeutics?

Summary

How does Elicio Therapeutics compare to Adagene?

Summary

How does Elicio Therapeutics compare to Compass Therapeutics?

Summary

How does Elicio Therapeutics compare to Oramed Pharmaceuticals?

Summary

How does Elicio Therapeutics compare to Precision BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. WHWK, ADAG, CMPX, ORMP, and DTIL

How does Elicio Therapeutics compare to Whitehawk Therapeutics?

Do analysts rate ELTX or WHWK?

Is ELTX or WHWK more profitable?

Do institutionals & insiders hold more shares of ELTX or WHWK?

Does the media favor ELTX or WHWK?

Which has more risk and volatility, ELTX or WHWK?

Which has better valuation & earnings, ELTX or WHWK?

Summary

How does Elicio Therapeutics compare to Adagene?

Which has higher earnings and valuation, ELTX or ADAG?

Is ELTX or ADAG more profitable?

Do institutionals and insiders hold more shares of ELTX or ADAG?

Does the media favor ELTX or ADAG?

Which has more volatility and risk, ELTX or ADAG?

Do analysts rate ELTX or ADAG?

Summary

How does Elicio Therapeutics compare to Compass Therapeutics?

Is CMPX or ELTX more profitable?

Do analysts rate CMPX or ELTX?

Does the media prefer CMPX or ELTX?

Do institutionals & insiders hold more shares of CMPX or ELTX?

Which has more volatility & risk, CMPX or ELTX?

Which has higher earnings and valuation, CMPX or ELTX?

Summary

How does Elicio Therapeutics compare to Oramed Pharmaceuticals?

Does the media refer more to ORMP or ELTX?

Which has higher valuation & earnings, ORMP or ELTX?

Do analysts prefer ORMP or ELTX?

Which has more risk & volatility, ORMP or ELTX?

Do institutionals and insiders have more ownership in ORMP or ELTX?

Is ORMP or ELTX more profitable?

Summary

How does Elicio Therapeutics compare to Precision BioSciences?

Is DTIL or ELTX more profitable?

Do insiders & institutionals have more ownership in DTIL or ELTX?

Do analysts recommend DTIL or ELTX?

Does the media refer more to DTIL or ELTX?

Which has preferable valuation & earnings, DTIL or ELTX?

Which has more volatility & risk, DTIL or ELTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools